Exploring Results from CAPItello-291 Trial

William J. Gradishar, MD, examines the impact of the CAPItello-291 phase III trial on NCCN breast cancer guidelines, comparing the investigated drug to other PI3K pathway inhibitors and discussing its potential to shape future treatment strategies.

EP: 1.NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer

EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024

EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

EP: 4.Tailoring CDK4/6 Inhibitor Treatment to Patient Needs

EP: 5.NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib

Now Viewing

EP: 6.Exploring Results from CAPItello-291 Trial

EP: 7.Exploring Biomarker Testing and Personalized Treatments in Breast Cancer

EP: 8.NCCN Guidelines Revisions and ASCO 2024 Research Outlook

EP: 9.Emerging Breast Cancer Therapies and Closing Thoughts

1. In November 2023, capivasertib received FDA approval for use in advanced hormone receptor-positive breast cancer based on the results from the CAPItello-291 phase III trial. How has capivasertib been integrated into the NCCN guidelines for breast cancer?
   1. What are your thoughts on sequencing of capivasertib use in the management of HR+ breast cancer?
2. How does capivasertib compare to other PI3K pathway inhibitors alpelisib and inavolisib from safety and efficacy standpoints?

Related Videos

Related Content

Advertisement

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils

Brooke McCormick

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.

June 6th 2025

5 Key FDA Approval Dates Mark a Milestone-Filled May

Brooke McCormick

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Related Content

Advertisement

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils

Brooke McCormick

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.

June 6th 2025

5 Key FDA Approval Dates Mark a Milestone-Filled May

Brooke McCormick

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.